Balaxi Pharmaceuticals Limited (BALAXI) AI Stock Analysis

• Market Cap: ₹476.44M
• Dividend Yield: N/A
• Average Volume (3M): 113.96K
• Price to Earnings (P/E): 11.9
• Beta (1Y): 0.98
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: IN
• Employees: 51
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Equipment & Services
• EPS (TTM): 0.26
• Shares Outstanding: 11,041,500
• 10 Day Avg. Volume: 98,208
• 30 Day Avg. Volume: 113,964
• PEG Ratio: -0.01
• Price to Book (P/B): 1.60
• Price to Sales (P/S): 1.28
• P/FCF Ratio: -6.29
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹48.00
• Price Target Upside: 11.24% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 64 Neutral
• Price Target: ₹48.00 ▲(11.24% Upside)

Balaxi Pharmaceuticals' overall stock score is driven primarily by its strong financial performance and attractive valuation. However, technical indicators suggest a bearish trend, which tempers the overall score. The lack of earnings call data and corporate events means these factors do not influence the score.

Balaxi Pharmaceuticals Limited Business Overview & Revenue Model

Company Description

Balaxi Pharmaceuticals Limited (BALAXI) is a rapidly growing pharmaceutical company that operates in the generic pharmaceutical sector. The company is primarily focused on the development, manufacturing, and distribution of a wide range of pharmaceutical products, including prescription and over-the-counter medications. Balaxi Pharmaceuticals emphasizes expanding its presence in emerging markets, leveraging its robust product portfolio and strategic distribution networks to meet the healthcare needs of diverse populations.

How the Company Makes Money

Balaxi Pharmaceuticals Limited generates revenue through the sale of its pharmaceutical products. The company's revenue model is based on manufacturing and distributing generic drugs, which are sold to healthcare providers, pharmacies, and distributors across various regions. The company has strategically positioned itself in emerging markets, where it capitalizes on the high demand for affordable medication. Balaxi's earnings are significantly influenced by its ability to maintain a strong supply chain, a diverse product offering, and strategic partnerships with local distributors and healthcare institutions. Additionally, the company invests in research and development to expand its product line and enhance its market competitiveness.

Balaxi Pharmaceuticals Limited Financial Statement Overview

Summary

Balaxi Pharmaceuticals shows strong revenue growth and a solid balance sheet with low leverage. However, inconsistent net income and negative cash flow in the latest fiscal year highlight potential risks that could impact financial health if not addressed.

Income Statement

Balaxi Pharmaceuticals has shown a strong revenue growth trajectory, with a notable increase from 2024 to 2025. The gross profit and EBIT margins are solid, reflecting good cost management and operational efficiency. However, the net profit margin has been inconsistent, with significant fluctuations in net income, indicating potential volatility in earnings.

Balance Sheet

The company's balance sheet shows a healthy equity ratio, indicating a strong capital structure with significant stockholders' equity relative to total assets. The debt-to-equity ratio is low, which minimizes financial risk. However, there has been a substantial increase in total debt in 2025, which could suggest a higher financial leverage moving forward.

Cash Flow

Balaxi Pharmaceuticals has faced challenges with negative free cash flow in 2025, driven by a significant increase in capital expenditures and operating cash flow turning negative. This raises concerns about cash management and sustainability of operations without external financing.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2021	Dec 2021
Income Statement
Total Revenue	2.68B	2.89B	2.41B	3.36B	2.31B	2.79B
Gross Profit	1.11B	1.18B	1.13B	1.34B	591.85M	837.91M
EBITDA	328.93M	305.64M	456.59M	591.75M	446.83M	551.76M
Net Income	273.66M	250.70M	-23.87M	459.63M	381.37M	476.58M
Balance Sheet
Total Assets	0.00	3.10B	2.58B	2.40B	996.80M	1.76B
Cash, Cash Equivalents and Short-Term Investments	608.67M	394.00M	622.91M	282.17M	16.69M	71.93M
Total Debt	0.00	534.25M	194.04M	133.06M	36.59M	36.38M
Total Liabilities	-2.16B	786.06M	569.79M	567.89M	347.00M	633.07M
Stockholders Equity	2.16B	2.32B	2.01B	1.83B	649.80M	1.13B
Cash Flow
Free Cash Flow	0.00	-589.01M	32.97M	-89.05M	-25.53M	68.00M
Operating Cash Flow	0.00	-377.82M	48.66M	60.75M	32.00K	341.44M
Investing Cash Flow	0.00	-217.64M	-10.46M	-105.65M	-59.73M	-284.48M
Financing Cash Flow	0.00	366.55M	302.54M	255.13M	36.46M	-1.63M

Balaxi Pharmaceuticals Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 43.15
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BALAXI, the sentiment is Negative. The current price of 43.15 is below the 20-day moving average (MA) of 45.71, below the 50-day MA of 46.87, and below the 200-day MA of 58.39, indicating a bearish trend. The MACD of -0.70 indicates Positive momentum. The RSI at 32.16 is Neutral, neither overbought nor oversold. The STOCH value of 9.60 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:BALAXI.

Balaxi Pharmaceuticals Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BALAXI	64 Neutral	₹476.44M	11.90	―	―	―	―
BIOFILCHEM	52 Neutral	₹679.76M	24.28	2.97%	―	-31.82%	341.44%
LASA	50 Neutral	₹589.69M	-1.78	-17.63%	―	25.82%	-69.86%
VIVIMEDLAB	37 Underperform	₹406.28M	―	90.88%	―	-24.33%	52.06%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Balaxi Pharmaceuticals Limited Corporate Events

Balaxi Pharmaceuticals Reports Strong Quarterly Financial Performance

Balaxi Pharmaceuticals Limited has announced the publication of its financial results for the quarter ended June 30, 2025, in prominent newspapers. The company reported a significant increase in revenue and net profit compared to the same quarter last year, reflecting strong operational performance. This financial disclosure is part of the company’s compliance with SEBI regulations and aims to keep stakeholders informed about its financial health.

Balaxi Pharmaceuticals Ensures Compliance with SEBI Regulations for Q2 2025

Balaxi Pharmaceuticals Limited has submitted a certificate to the National Stock Exchange of India, confirming compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ending June 30, 2025. This compliance involves the dematerialization of securities, ensuring that securities are listed on the appropriate stock exchanges, and updating records to reflect the depository as the registered owner, which is crucial for maintaining regulatory standards and operational transparency.